OPRX NASDAQ
OptimizeRx Corporation
1W: -4.6%
1M: -27.4%
3M: -39.8%
YTD: -60.2%
1Y: -58.7%
3Y: -60.4%
5Y: -88.9%
$4.94
+0.00 (+0.00%)
Weekly Expected Move ±13.2%
$4
$5
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
2 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (56)
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?
OptimizeRx (OPRX) Q1 2026 Earnings Transcript
OptimizeRx Corporation Q1 2026 Earnings Call Summary
OptimizeRx forecasts $95M-$100M 2026 revenue while maintaining $21M-$25M adjusted EBITDA amid pharma MFN disruption
OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates
12 Health Care Stocks Moving In Tuesday's After-Market Session
OptimizeRx Expands EHR Advertising Reach With New DSP Integration
Here are the major earnings after the close Tuesday
Earnings Scheduled For May 12, 2026
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
SNDK's Q3 Earnings Beat Estimates, Revenues Rise on Datacenter Surge
Smith Micro Software, Inc. (SMSI) Reports Q1 Loss, Tops Revenue Estimates
Cadence Design Systems (CDNS) Q1 Earnings and Revenues Top Estimates
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
Will Enterprise Deals & MedTech Momentum Fuel OPRX's Growth Engine?
Pegasystems (PEGA) Misses Q1 Earnings and Revenue Estimates
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX Trades at a Discount to Industry: How to Approach the Stock Now?
Should Value Investors Buy OptimizeRx (OPRX) Stock?
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
New Strong Buy Stocks for April 1st
Best Value Stocks to Buy for April 1st
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock?
Best Value Stocks to Buy for March 24th
New Strong Buy Stocks for March 24th
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Is OptimizeRx (OPRX) Stock Undervalued Right Now?
Best Value Stocks to Buy for March 16th
OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty
12 Health Care Stocks Moving In Friday's Intraday Session
OptimizeRx signals $109M-$114M revenue target for 2026 as market shifts drive cautious outlook
OptimizeRx (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
12 Health Care Stocks Moving In Thursday's After-Market Session
OptimizeRx Non-GAAP EPS of $0.51 beats by $0.29, revenue of $32.2M beats by $1.29M
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings after the close Thursday
Earnings Scheduled For March 5, 2026
OptimizeRx Q4 2025 Earnings Preview
Smith Micro Software, Inc. (SMSI) Reports Q4 Loss, Misses Revenue Estimates
Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag
Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $21.00
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
Strength Seen in OptimizeRx (OPRX): Can Its 7.5% Jump Turn into More Strength?
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story
OptimizeRx (NASDAQ:OPRX) Insider Edward Stelmakh Sells 1,388 Shares of Stock
OptimizeRx Continues Expansion of the Company's Point-Of-Care Network